Company / Depreciation & Amortization
10x Genomics, Inc. Depreciation & Amortization History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$36.2M
FY2025
5-year range
$7.1M / $36.2M
FY2021-FY2025
Trend
+0.9%
vs FY2024
Sector context
#89 of 141
Health Care
What the data says
At $36M, 10x Genomics, Inc.'s depreciation & amortization ranks #53 of 141 in the Health Care sector. Depreciation & Amortization has increased for 4 consecutive years, from $7M in FY2021 to $36M in FY2025.
Based on SEC 10-K filings.
$36M in FY2025 with a 5-year CAGR of +20.9%.
Remained stable around $36M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +37.2%
- 5-Year CAGR
- +20.9%
- 10-Year CAGR
- -
Sector benchmark
#53 of 141 in Health CareTop 37% of 141This company $36.2M Sector average $344.6M
▼
-89.5% below sector average
Key checks
Key Insights
- 10x Genomics, Inc.'s depreciation & amortization has grown for 4 consecutive years.
- 5-year CAGR of +20.9%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 0.9% year-over-year.
- Ranks #89 out of 141 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $36.2M | +0.9% |
| FY2024 | $35.9M | +1.0% |
| FY2023 | $35.5M | +153.4% |
| FY2022 | $14.0M | +98.3% |
| FY2021 | $7.1M | -49.6% |
| FY2020 | $14.0M | +98.3% |
| FY2019 | $7.1M | +80.9% |
| FY2018 | $3.9M | -9.3% |
| FY2017 | $4.3M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026